This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2003 May;52(5):767; author reply 767-7.

doi: 10.1136/gut.52.5.767.

TPMT in the treatment of inflammatory bowel disease with azathioprine

A Qasim, J Seery, M Buckley, C O Morain

PMID: 12692068
PMCID: PMC1773647
DOI: 10.1136/gut.52.5.767

Comment

TPMT in the treatment of inflammatory bowel disease with azathioprine

A Qasim et al. Gut. 2003 May.

. 2003 May;52(5):767; author reply 767-7.

doi: 10.1136/gut.52.5.767.

Authors

A Qasim, J Seery, M Buckley, C O Morain

PMID: 12692068
PMCID: PMC1773647
DOI: 10.1136/gut.52.5.767

No abstract available

PubMed Disclaimer

Figures

Figure 1
Time of occurrence for various toxicities during azathioprine therapy. *Onset of toxicity relates to time (in months) from the start of azathioprine treatment to the appearance/detection of toxicity. SE, side effects.

See this image and copyright information in PMC

Comment on

TPMT in the treatment of Crohn's disease with azathioprine.
Lennard L. Lennard L. Gut. 2002 Aug;51(2):143-6. doi: 10.1136/gut.51.2.143. Gut. 2002. PMID: 12117866 Free PMC article.

Similar articles

Normal thiopurine methyltransferase levels do not eliminate 6-mercaptopurine or azathioprine toxicity in children with inflammatory bowel disease.
Kader HA, Wenner WJ Jr, Telega GW, Maller ES, Baldassano RN. Kader HA, et al. J Clin Gastroenterol. 2000 Jun;30(4):409-13. doi: 10.1097/00004836-200006000-00011. J Clin Gastroenterol. 2000. PMID: 10875470
Long-term Safety and Efficacy of Low-dose Azathioprine and Allopurinol Cotherapy in Inflammatory Bowel Disease: A Large Observational Study.
Pavlidis P, Stamoulos P, Abdulrehman A, Kerr P, Bull C, Duley J, Ansari A. Pavlidis P, et al. Inflamm Bowel Dis. 2016 Jul;22(7):1639-46. doi: 10.1097/MIB.0000000000000827. Inflamm Bowel Dis. 2016. PMID: 27271488
Choice of azathioprine or 6-mercaptopurine dose based on thiopurine methyltransferase (TPMT) activity to avoid myelosuppression. A prospective study.
Gisbert JP, Luna M, Maté J, González-Guijarro L, Cara C, Pajares JM. Gisbert JP, et al. Hepatogastroenterology. 2006 May-Jun;53(69):399-404. Hepatogastroenterology. 2006. PMID: 16795981 Clinical Trial.
Treatment of inflammatory bowel disease with azathioprine: how to use it in 1999.
Louis E, Belaiche J. Louis E, et al. Acta Gastroenterol Belg. 1999 Oct-Dec;62(4):437-9. Acta Gastroenterol Belg. 1999. PMID: 10692777 Review.
Azathioprine induced colitis: a case report and review of the literature.
Bossuyt P, Vergauwe P, Inderadjaja N, Vermeire S. Bossuyt P, et al. Acta Gastroenterol Belg. 2007 Jul-Sep;70(3):302-5. Acta Gastroenterol Belg. 2007. PMID: 18074743 Review.

See all similar articles

Cited by

The thiopurines: an update.
Coulthard S, Hogarth L. Coulthard S, et al. Invest New Drugs. 2005 Dec;23(6):523-32. doi: 10.1007/s10637-005-4020-8. Invest New Drugs. 2005. PMID: 16267626 Review.
Thiopurine monitoring in children with inflammatory bowel disease: a systematic review.
Konidari A, Anagnostopoulos A, Bonnett LJ, Pirmohamed M, El-Matary W. Konidari A, et al. Br J Clin Pharmacol. 2014 Sep;78(3):467-76. doi: 10.1111/bcp.12365. Br J Clin Pharmacol. 2014. PMID: 24592889 Free PMC article.
Genotype-Guided Thiopurine Dosing Does not Lead to Additional Costs in Patients With Inflammatory Bowel Disease.
Sluiter RL, Van Marrewijk C, De Jong D, Scheffer H, Guchelaar HJ, Derijks L, Wong DR, Hooymans P, Vermeulen SH, Verbeek ALM, Franke B, Van der Wilt GJ, Kievit W, Coenen MJH. Sluiter RL, et al. J Crohns Colitis. 2019 Jul 25;13(7):838-845. doi: 10.1093/ecco-jcc/jjz009. J Crohns Colitis. 2019. PMID: 30698675 Free PMC article. Clinical Trial.
The long-term risk of continuous immunosuppression using thioguanides in inflammatory bowel disease.
O'Connor A, Qasim A, O'Moráin CA. O'Connor A, et al. Ther Adv Chronic Dis. 2010 Jan;1(1):7-16. doi: 10.1177/2040622310368736. Ther Adv Chronic Dis. 2010. PMID: 23251725 Free PMC article.
Risk-stratified monitoring for thiopurine toxicity in immune-mediated inflammatory diseases: prognostic model development, validation, and, health economic evaluation.
Nakafero G, Card T, Grainge MJ, Williams HC, Taal MW, Aithal GP, Fox CP, Mallen CD, van der Windt DA, Stevenson MD, Riley RD, Abhishek A. Nakafero G, et al. EClinicalMedicine. 2023 Sep 14;64:102213. doi: 10.1016/j.eclinm.2023.102213. eCollection 2023 Oct. EClinicalMedicine. 2023. PMID: 37745026 Free PMC article.

See all "Cited by" articles

References

1. Campbell S, Kingstone K, Ghosh S. Relevance of thiopurine methyltransferase activity in inflammatory bowel disease patients maintained on low dose azathioprine. Aliment Pharmacol Ther 2002;16:389–98. - PubMed
1. Connell WR, Kamm MA, Ritchie JK, et al. Bone marrow toxicity caused by azathioprine in inflammatory bowel disease: 27 years of experience. Gut 1993;34:1081–5. - PMC - PubMed
1. Hanauer SB, Sandborn W and The Practice Parameter Committee of the American College of Gastroenterology. Management of Crohn’s disease in adults. Am J Gastroenterol 2001;96:635–43. - PubMed
1. Lennard L, Van Loon JA, Weinshilboum RM. Pharmacogenetics of acute azathioprine toxicity: Relationship to thiopurine methyltransferase genetic polymorphism. Clin Pharmacol Ther 1989;46:149–54. - PubMed
1. Black AJ, McLeod H, Capell HA, et al. Thiopurine methyltransferase genotype predicts therapy-limiting severe toxicity from azathioprine. Ann Intern Med 1998;129:716–18. - PubMed

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
Medical
- MedlinePlus Health Information